Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
InMed Pharmaceuticals (INM)
NASDAQ:INM
RESEARCH TOOLSreports
Holding INM?
Track your performance easily
INM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.41 - $15.69
Previous Close$4.65
Volume32.75K
Average Volume (3M)53.27K
Market Cap
$3.34M
Enterprise Value-$2.31M
Total Cash (Recent Filing)$6.61M
Total Debt (Recent Filing)$962.66K
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Feb 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding667,672
10 Day Avg. Volume57,614
30 Day Avg. Volume53,269
Standard Deviation0.26
R-Squared0.02
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)0.31
Price to Sales (P/S)0.63
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.50
Enterprise Value/Gross Profit-2.10
Enterprise Value/Ebitda0.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
InMed Pharmaceuticals News
PremiumCompany Announcements
InMed Pharmaceuticals Explores CBN for Skin Disease Treatment
PremiumCompany Announcements
InMed’s Study Highlights Cannabinol’s Potential in Skincare
PremiumCompany Announcements
InMed Pharmaceuticals Reports Improved Quarterly Earnings
PremiumCompany Announcements
InMed Pharmaceuticals Makes Progress on Alzheimer’s Drug
PremiumCompany Announcements
InMed Pharmaceuticals to Consolidate Shares for Nasdaq CompliancePremiumCompany Announcements
InMed Pharmaceuticals’ New Alzheimer’s Treatment Patent
PremiumCompany Announcements
InMed Pharmaceuticals Showcases INM-901 at Biotech WebinarOwnership Overview
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
INM FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was $2.41 and its highest was $15.69 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
Currently, no data Available
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is Feb 18, 2025 which is in 87 days.
How were InMed Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 718,032 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in INM
---
InMed Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.8%
Last 30 Days ▲ 14.7%
Last 30 Days ▲ 14.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.83%
12-Months-Change
Fundamentals
Return on Equity
-75.85%
Trailing 12-Months
Asset Growth
-4.14%
Trailing 12-Months
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals, Inc. engages in the research and development of cannabinoid-based therapies and biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. It offers pipeline of medications that target diseases with unmet medical needs, such as epidermolysis bullosa, glaucoma, and orofacial pain. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
---
Technical Analysis
AXIM Biotechnologies
―
Corbus Pharmaceuticals
―
Outlook Therapeutics
―
Sorrento Therapeutics
―
---